Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
about
Novel agents in the treatment of multiple myeloma: a review about the futureMultiple myeloma in the very elderly patient: challenges and solutionsTargeted treatments for multiple myeloma: specific role of carfilzomibA clinical update on the role of carfilzomib in the treatment of relapsed or refractory multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyThe acute respiratory distress syndrome: from mechanism to translationHeart failure secondary to carfilzomib-induced heart block in multiple myeloma patients.Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Drugs acting on homeostasis: challenging cancer cell adaptation.Curing myeloma at last: defining criteria and providing the evidence.Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceGeriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma.The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary reMyeloma today: Disease definitions and treatment advances.A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myelomaRevised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.ESRD due to Multiple Myeloma in the United States, 2001-2010.Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.Carfilzomib boosted combination therapy for relapsed multiple myelomaCarfilzomib in multiple myeloma.The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.New pharmacotherapy options for multiple myeloma.The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).Which therapies will move to the front line for multiple myeloma?A practical review on carfilzomib in multiple myeloma.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Sorafenib for the treatment of multiple myeloma.How is patient care for multiple myeloma advancing?Safety of proteasome inhibitors for treatment of multiple myeloma.Second primary malignancies in multiple myeloma: an overview and IMWG consensus.Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century.Spasmogenic Effects of the Proteasome Inhibitor Carfilzomib on Coronary Resistance, Vascular Tone and Reactivity.Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis.Predicting Risk of Infection in Patients with Newly Diagnosed Multiple Myeloma: Utility of Immune ProfilingCarfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
P2860
Q26745924-338C5FC5-DB47-400F-8657-6CD177BF8E37Q26752991-2B35C9D5-9FCE-49EC-B9A5-176DF824D66AQ26996524-585AF09D-1933-406C-8765-907991A6E6F4Q28067148-30588E4A-DEDC-483A-946A-27877EAA0D1EQ28082910-04856493-5ECB-42A6-9673-2BC9099186D1Q28386068-0368D945-66AA-4E15-A865-865713806614Q33429346-395FD24A-8A36-415B-A07B-73362FFD892FQ33785935-4957B006-B42C-4754-926A-E66B64B0BA3DQ34500113-EF02CC0E-E915-4613-A563-10960121722BQ34508313-374B2624-90A4-4562-8C52-98BD08B50B9DQ35070412-3B618C5B-BBD3-4F48-A61E-3111BE29BB77Q35220639-DE9213E6-3A55-42A6-BDB2-3AD5A9A9A46EQ35886785-05BC2EEC-42F2-489B-B378-01082BEE58DDQ36020680-4BE097DC-D68A-44AF-B812-912D4E9BD784Q36470699-FF8E462B-16ED-4895-881E-5DCF941E61FEQ36671445-85BD7B74-F142-43CB-9129-EB2516BCE928Q36839385-DC06DE2B-96BE-492E-8CEA-FA2F6A80790AQ36849170-E8FAF46F-C0C1-40ED-AE3F-A86E51E49C1BQ37623809-E7B26D3E-38A4-4CB0-91E2-94D09046A8E1Q37652953-F1685617-DE95-4F04-ADC4-74F1058CAE99Q38244558-360C3DF0-9F37-4E7D-923A-E559FD34D93CQ38400460-7F1CD22D-7E56-482D-858A-FC6056A4782BQ38673764-245705E8-DFBA-407A-9540-3B6E6F6F962EQ38685108-AC1D3AEC-573A-48AB-9EE4-21E8785F4851Q38688055-9352A003-CFC7-4692-A716-CCEC94939ABCQ38733592-B92E9919-7784-406C-A184-896243C03937Q38740271-771ADA78-224D-44D8-8A51-0E5C1216FC26Q38756800-AB64464D-F578-4D84-9DFC-3320BBDD3F60Q38783055-63B42333-A81F-405C-A612-1512BA2961B4Q38786149-3767CBB5-6528-47A1-AA52-5E4FD360F6CDQ39007504-27D6234C-D8AC-4D52-A3F2-E267BC8C78ECQ39013620-B8B88B51-3C35-410A-B868-7FECE14859C5Q39177792-C2104BD5-AE9B-48AB-84FE-4FFA73956D47Q39234159-D788C56B-462B-482C-A5AE-8B7147CC9218Q40582501-1D3B0C79-937A-46EC-81FA-D3E5BCB9DC86Q40784538-318B5D9D-2859-4F74-98AF-E084289E2480Q41040725-2AEE64C6-676D-4BC2-9DA8-44117F1B1847Q41396044-3B666340-BE5E-43A8-B7F9-96DD6C946F08Q42373431-ABE43325-E2C4-49C8-838A-A60C787FC3ECQ47236245-1CC11987-4E4F-4B9D-9DA9-826D63D865E0
P2860
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
description
im Juli 2014 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в липні 2014
@uk
name
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@en
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@nl
type
label
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@en
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@nl
prefLabel
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@en
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@nl
P2093
P50
P1433
P1476
Carfilzomib, cyclophosphamide, ...... : a multicenter, phase 2 study
@en
P2093
Concetta Conticello
Davide Rossi
Fabiana Gentilini
Giulia Benevolo
Luana Boccadifuoco
Maria Teresa Petrucci
Mariella Genuardi
Mario Boccadoro
Paola Omedé
Paola Tacchetti
P356
10.1182/BLOOD-2014-03-563759
P407
P50
P577
2014-07-03T00:00:00Z